Abstract:Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC50 < 200 nM). Additionally, lysine methyltransferase G9a inhibitory activity is achieved (from a low nanomolar range) by introduction of a key lysine mimic group at the 7-position of the quinoline ring. The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising in vitro activity of 12a (CM-444) with GI50 of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. In vivo, 12a achieved significant antitumor efficacy in a xenograft mouse model of human multiple myeloma.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02255?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02255</a>.Protocols for preparative HPLC purification methods; method for high-resolution mass spectrometry (HRMS) of the final compounds; methods for analytical HPLC and UHPLC; HPLC or UHPLC traces of the final compounds; NMR spectra (1H & 13C) of the final compounds; biochemical profiling of 9a and 12aversus DNMT and HDAC isoforms; H3K9me2 and H3Ac marks after treatment with A-366, Panobinostat, and Decitabine in MM1.S cells; hypomethylating activity of compounds 9a and 12a in JJN3 cells; body weight of mice treated with compound 12a; and plasmatic concentrations of 12a after administration (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_001.pdf">PDF</a>)Molecular formula strings together with their IC50 values (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_002.csv">CSV</a>)Results from docking studies reported in Figure 2:G9a compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_003.pdb">PDB</a>)DNMT1 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_004.pdb">PDB</a>)HDAC1 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_005.pdb">PDB</a>)HDAC6 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment

Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP

Regioselective covalent modification of hemoglobin in search of antisickling agents

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity

Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor

Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehyde as Drug Candidates for the Treatment of Sickle Cell Disease

Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors

Detailed Exploration Around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.

Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease

Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma

Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment

Covalent inhibition of NSD1 histone methyltransferase

Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde

Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease

Structure−Activity Relationship Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase Inhibitors: Discovery of SphK1- and SphK2-Selective Inhibitors

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions